A novel phospholipid-based drug formulation, VP025, modulates age- and LPS-induced microglial activity in the rat.
BACKGROUND
A common change that occurs with age in the central nervous system is an increase in microglial-associated inflammation. This is usually coupled with an increase in the concentration of the inflammatory cytokine interleukin-1beta (IL-1beta) in the hippocampus and an inhibition in long-term potentiation.


OBJECTIVE
To assess the effects of a novel preparation of phospholipid nanoparticles incorporating phosphatidylglycerol, VP025, on inflammatory changes in hippocampus of aged and lipopolysaccharide (LPS)-treated rats.


RESULTS
We report that a possible initial target cell of the putative anti-inflammatory actions of VP025 may be macrophages, as VP025 is engulfed by, and has the capacity to alter the activity of, these cells. VP025 reversed the increase in IFN-gamma concentration in supernatant taken from peritoneal macrophages harvested from LPS-treated rats. In addition, markers of microglial activity, major histocompatibility complex class II (MHC II) mRNA expression, CD40 expression and IL-1beta concentration were increased, and CD200 expression was reduced, in the hippocampus of these rats. VP025 reversed changes in CD40, IL-1beta and CD200 in aged rats, and also restored long-term potentiation in aged and LPS-treated rats.


CONCLUSIONS
We conclude that VP025 has the ability to modulate the activity of macrophage, microglia and neurons in response to stressors such as ageing and LPS treatment.
Martin
Darren S D
DS
Vasogen Ireland Ltd., Trinity College Institute of Neuroscience, Physiology Department, Trinity College, Dublin, Ireland.
Walsh
Michelle
M
Miller
Anne-Marie
AM
Skerrett
Helen E
HE
Byrne
Patricia
P
Mandel
Arkady
A
Bolton
Anthony E
AE
Lynch
Marina A
MA
D000328:Adult; D000375:Aging / Q000502:physiology*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000494:pharmacology*; D004660:Encephalitis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D005911:Gliosis / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D056747:Immunomodulation / Q000187:drug effects / Q000502:physiology; D007371:Interferon-gamma / Q000378:metabolism; D053583:Interleukin-1beta / Q000378:metabolism; D017774:Long-Term Potentiation / Q000187:drug effects / Q000502:physiology; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008569:Memory Disorders / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D017628:Microglia / Q000187:drug effects* / Q000502:physiology; D053758:Nanoparticles / Q000737:chemistry; D019580:Perforant Pathway / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D010587:Phagocytosis / Q000187:drug effects / Q000502:physiology; D010715:Phosphatidylglycerols / Q000737:chemistry / Q000494:pharmacology*; D010743:Phospholipids / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D053583:Interleukin-1beta; D010715:Phosphatidylglycerols; D010743:Phospholipids; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma